National Institutes of Health (NIH) And Santhera Pharmaceuticals AG Announce Positive Results Of Study With SNT-MC17/idebenone In Friedreich’s Ataxia (FRDA)

Bethesda, Maryland, USA, and Liestal, Switzerland - The US National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH) presented results of their recently completed clinical trial with SNT-MC17/idebenone in Friedreich's Ataxia (FRDA). Data were presented by Dr. Nicholas Di Prospero at the 3rd International Scientific Friedreich's Ataxia Conference in Bethesda, MD, on November 10
MORE ON THIS TOPIC